OncoMatch

OncoMatch/Clinical Trials/NCT06511037

PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis

Is NCT06511037 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies Pafolacianine (CYTALUX) with intraoperative fluorescent near-infrared (NIR) imaging for gastrointestinal cancer.

Early Phase 1RecruitingUniversity of California, IrvineNCT06511037Data as of Jun 2026

Treatment: Pafolacianine (CYTALUX) with intraoperative fluorescent near-infrared (NIR) imagingThis is a pilot, single-arm, open label study to evaluate the ability of CYTALUX™ (pafolacianine) to help identify cancerous lesions in subjects with gastrointestinal cancers and peritoneal carcinomatosis during cytoreductive surgery.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Pafolacianine (CYTALUX) with intraoperative fluorescent near-infrared (NIR) imaging

Cancer type

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Cholangiocarcinoma

Esophageal Carcinoma

Ovarian Cancer

Prior therapy

Cannot have received: pafolacianine (cytalux, pafolacianine)

Cannot have received: investigational agent

Lab requirements

Kidney function

eGFR <50 mL/min/1.73m2 excluded

Liver function

ALT, AST, ALP, or total bilirubin >3x ULN excluded

Impaired renal function defined as eGFR <50 mL/min/1.73m2; Impaired liver function defined as values >3x the upper limit of normal (ULN) for alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total bilirubin; Clinically significant abnormalities on ECG

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Chao Family Comprehensive Cancer Center, University of California, Irvine · Orange, California

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06511037 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior pafolacianine, investigational agent disqualifies patients from enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify